Researchers reporting in PLOS One describe the development of a biphasic release tablet-in-tablet formulation containing ketorolac tromethamine, a widely used NSAID for moderate to severe pain. The work focuses on drug delivery design rather than a new active ingredient, aiming to improve how ketorolac is released in the body.
Ketorolac tromethamine is known for strong pain-relieving effects, but its short elimination half-life can make repeated dosing necessary. That frequent schedule may be inconvenient for patients and can affect treatment adherence, which is why a modified-release approach is of interest.
A biphasic release system is intended to provide two release patterns in one dosage form: an initial portion for earlier drug availability and a second portion for a more prolonged effect. In a tablet-in-tablet format, those release phases are built into a single tablet structure, potentially combining rapid onset with extended delivery.
Based on the study description, the main objective was to formulate this ketorolac tablet system as a way to support pain management while reducing the need for frequent dosing. The research adds to ongoing efforts to refine oral drug delivery for established pain medicines, although the snippet does not detail full study results or clinical outcomes.
